Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 18/20 | 0.66 |
| ▸ | HPGD | P15428 | 2/20 | 0.60 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.60 |
| ▸ | MGAM | O43451 | 1/20 | 0.46 |
| ▸ | F2 | P00734 | 1/20 | 0.46 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | SI | P14410 | 1/20 | 0.46 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.46 |
| ▸ | RXRA | P19793 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7537331 | 0.87 | HCAR3 (0.62) | HCAR3HPGDHCAR2RXRAPPARG | |
| SCHEMBL7232454 | 0.86 | HCAR3 (0.53) | HCAR3HPGDHCAR2MGAMF2 | |
| SCHEMBL18033711 | 0.82 | HCAR3 (0.60) | HCAR3HPGDHCAR2 | |
| SCHEMBL5921944 | 0.81 | HCAR3 (0.68) | HCAR3HPGDHCAR2 | |
| SCHEMBL18033712 | 0.79 | HCAR3 (0.60) | HCAR3HPGDHCAR2 | |
| SCHEMBL4054573 | 0.79 | KCNMA1 (0.61) | HCAR3HPGDHCAR2MGAMF2 | |
| SCHEMBL10428898 | 0.79 | KCNMA1 (0.61) | HCAR3HPGDMGAMF2AMY1A | |
| SCHEMBL599138 | 0.79 | HCAR3 (1.00) | HCAR3HPGDHCAR2KMT2A | |
| SCHEMBL8424378 | 0.79 | HCAR3 (0.66) | HCAR3HPGDHCAR2RXRAPPARG | |
| SCHEMBL4958365 | 0.79 | KDM4E (0.53) | HCAR3HPGDHCAR2MGAMF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6515124-B2 | (Z)-2-((2-bromo-4-(((3-hydroxybenzyl)amino)carbonyl)benzoyl) -amino)pent-2-enoic acid, for example; useful for treating psoriasis | HOFFMAN-LA ROCHE INC. | 2003-02-04 | — | — | US | disclosed |
| EP-1261579-A1 | DEHYDROAMINO ACIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-12-04 | — | — | EP | disclosed |
| US-20020161237-A1 | Dehydroamino acids | HOFFMANN-LA ROCHE INC. | 2002-10-31 | — | — | US | disclosed |
| WO-2001058853-A1 | DEHYDROAMINO ACIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020161237-A1 | Dehydroamino acids | HSD3B1, CYP8B1, TH | HCAR3 31/4885HPGD 153/4885HCAR2 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.